Dr Reddy's Launches Cancer Drug Abiraterone Acetate In US Market
The drug is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson
Topics
Dr Reddy's Laboratories Limited | cancer drug | Dr Reddy’s cancer drug
BS Reporter |

The drug, which is used in cancer treatment, is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson.
Dr Reddy's Laboratories Limited today announced the launch of Abiraterone Acetate Tablets in the US market, following approval from the US Food and Drug Administration (USFDA).
The drug, which is used in cancer treatment, is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson.
Abiraterone Acetate is a significant launch for the company, as the Zytiga brand and generic market had US sales of approximately $454 million for the most recent twelve months ending in March 2020 according to IQVIA Health.
First Published: Fri, June 19 2020. 15:30 IST
';if(neverShowNotificaitonCookie==''||neverShowNotificaitonCookie=='undefined'||neverShowNotificaitonCookie==null){var lastReminderCookie=getCookie('_ler'+loginParamObj.uId);if((lastReminderCookie=="")||(lastReminderCookie=="undefined")||(lastReminderCookie==null)){$('body').prepend(notificationBox);}else{if(lastReminderCookie
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
Bank Of London Continues To Rebuild
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
JPMorgan's Berlin Moment: Chase Takes On Europe
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
What Strategy's Bitcoin Sale Really Tells Us
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more

